Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) FCF Margin (2016 - 2026)

Ocular Therapeutix has reported FCF Margin over the past 13 years, most recently at 624.2% for Q1 2026.

  • For Q1 2026, FCF Margin fell 18857.0% year-over-year to 624.2%; the TTM value through Mar 2026 reached 435.78%, down 18889.0%, while the annual FY2025 figure was 396.64%, 18510.0% down from the prior year.
  • FCF Margin for Q1 2026 was 624.2% at Ocular Therapeutix, down from 349.07% in the prior quarter.
  • Over five years, FCF Margin peaked at 52.99% in Q3 2023 and troughed at 624.2% in Q1 2026.
  • A 5-year average of 237.55% and a median of 163.3% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 9343bps in 2022 and later crashed -26430bps in 2025.
  • Year by year, FCF Margin stood at 143.49% in 2022, then rose by 21bps to 113.79% in 2023, then tumbled by -103bps to 231.09% in 2024, then tumbled by -51bps to 349.07% in 2025, then plummeted by -79bps to 624.2% in 2026.
  • Business Quant data shows FCF Margin for OCUL at 624.2% in Q1 2026, 349.07% in Q4 2025, and 389.98% in Q3 2025.